Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
600 participants
OBSERVATIONAL
2022-11-01
2025-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Does Increasing Oxygen Nurture Your Symptomatic Ischemic Ulcer Sufficiently?
NCT05804097
Adjunctive Hyperbaric Oxygen Therapy (HBOT) for Lower Extermity Diabetic Ulcer:
NCT03675269
Hyperbaric Oxygen Therapy in Diabetic Foot
NCT06502808
Hyperbaric Oxygen Therapy as Adjunctive Treatment of Chronic Diabetic Foot Ulcers
NCT00953186
Hyperbaric Oxygen Therapy (HBOT) for Chronic Diabetic Lower Limb Ulcers
NCT00621608
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HBOT
Received complementary HBOT
HBOT
Hyperbaric Oxygen Therapy
Control
Standard care therapy
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HBOT
Hyperbaric Oxygen Therapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Meggitt-Wagner classification grade 2-4, existing \> 4 weeks
* Complete 1 year follow-up
Exclusion Criteria
* Treatment with chemotherapy, immunosuppressive drugs or systemic corticosteroids within the last 3 months
* Metastasized malignancy
* Left ventricular ejection fraction (EF) \<20% or external pacemaker
* Recent thoracic or middle ear surgery
* Severe epilepsy
* Uncontrollable high fever
* Pregnancy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dirk T. Ubbink
Prof.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Joost R Meijering, MD
Role: STUDY_CHAIR
Amsterdam University Medical Center
Dirk T Ubbink, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Amsterdam University Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Amsterdam UMC
Amsterdam, North Holland, Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Joost R Meijering, MD
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024.0066
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.